Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | FAAH | O00519 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19779563 | 0.80 | GABRA1 (0.61) | GABRA1GABRB1GABRB2GABRG2GABRB3 | |
| SCHEMBL310825 | 0.80 | GABRA1 (0.61) | GABRA1GABRB1GABRB2GABRG2GABRB3 | |
| SCHEMBL13273489 | 0.80 | GABRA1 (0.61) | GABRA1GABRB1GABRB2GABRG2GABRB3 | |
| SCHEMBL56243 | 0.79 | GABRA1 (0.44) | GABRA1GABRB1GABRB2GABRG2GABRB3 | |
| SCHEMBL29717597 | 0.79 | GABRA1 (0.44) | GABRA1GABRB1GABRB2GABRG2GABRB3 | |
| SCHEMBL29763599 | 0.78 | GABRA1 (0.59) | GABRA1GABRB1GABRB2GABRG2GABRB3 | |
| Propofol SCHEMBL2414429 | 0.78 | GABRA1 (1.00) | GABRA1GABRB1GABRB2GABRG2GABRB3 | |
| SCHEMBL4962062 | 0.78 | ALDH1A1 (0.46) | GABRA1GABRB2CA1CA2HPGD | |
| Propofol SCHEMBL36245 | 0.78 | GABRA1 (1.00) | GABRA1GABRB1GABRB2GABRG2GABRB3 | |
| SCHEMBL16955337 | 0.78 | GABRA1 (0.41) | GABRA1GABRB1GABRB2GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256510-B1 | PROCESS AND SYSTEM FOR PRODUCTION OF POLYPROPIOLACTONE | NOVOMER INC (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2016131001-A9 | PROCESS AND SYSTEM FOR PRODUCTION OF POLYPROPIOLACTONE | NOVOMER INC. (US) | 2017-07-13 | — | — | WO | disclosed |
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| CN-101115734-A | Spiro derivatives as lipoxygenase inhibitors | LILLY CO ELI (US) | 2008-01-30 | — | — | CN | disclosed |
| EP-1836183-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | Galileo Pharmaceuticals, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006065686-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | GALILEO PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | ALOX15B, ALOX5, ALOX15 | GABRA1 3804/4885GABRB1 3582/4885GABRB2 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.